Enpath Medical receives CE Mark for steerable sheath

By Lisa Kerner

Erie, Pa., Jan. 6 - Enpath Medical Inc. has received CE Mark approval for its steerable sheath technology used in the delivery of carotid artery stents and other peripheral vessel interventions.

Enpath's distribution partner Bard Electrophysiology, a division of C.R. Bard, will launch the steerable sheath in Europe for electrophysiology applications.

"The EP [electrophysiology] market is the first of a variety of clinical applications that can benefit from the use of our steerable sheaths," said Jim Hartman, Enpath's chairman and chief executive officer, in a news release.

Enpath's steerable sheath features distal tip deflection for precise placement of devices such as cardiac ablation catheters and peripheral stent delivery catheters

The company received U.S. Food and Drug Administration clearance for the technology in July.

Enpath Medical, with headquarters in Plymouth, Minn., specializes in percutaneous delivery systems and stimulation leads technologies.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.